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Abstract: A fatal case of butyrfentanyl poisoning was investigated at the Zurich Institute of Forensic
Medicine. At admission at the institute approx. 9 h after death (first time point, t1), femoral and heart
blood (right ventricle) was collected, as well as samples from the lung, liver, kidney, spleen, muscle and
adipose tissue using computed tomography (CT)-guided biopsy sampling. At autopsy (t2), samples from
the same body regions were collected manually. Additionally, urine, heart blood (left ventricle), gastric
content, brain samples and hair were collected. Butyrfentanyl concentrations and relative concentrations
of the metabolites carboxy-, hydroxy-, nor-, and desbutyrfentanyl were determined by LC฀MS/MS and
LC-QTOF. At t1, butyrfentanyl concentrations were 66 ng/mL in femoral blood, 39 ng/mL in heart
blood, 110 ng/g in muscle, 57 ng/g in liver, 160 ng/g in kidney, 3100 ng/g in lung, 590 ng/g in spleen and
550 ng/g in adipose tissue. At t2, butyrfentanyl concentration in urine was 1100 ng/mL, in gastric content
2000 ng/mL, in hair 11,000 pg/mg and brain concentrations ranged between 200฀340 ng/g. Carboxy- and
hydroxybutyrfentanyl were identified as most abundant metabolites. Comparison of t1 and t2 showed a
concentration increase of butyrfentanyl in femoral blood of 120%, in heart blood of 55% and a decrease
in lung of 30% within 19 h. No clear concentration changes could be observed in the other matrices.
Postmortem concentration changes were also observed for the metabolites. In conclusion, butyrfentanyl
seems to be prone to postmortem redistribution processes and concentrations in forensic death cases
should be interpreted with caution.
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A fatal case of butyrfentanyl poisoning was investigated at the Zurich Institute of Forensic Medicine. At 
admission at the institute approx. 9 hours after death (first time point, t1), femoral and heart blood (right 
ventricle) was collected, as well as samples from the lung, liver, kidney, spleen, muscle and adipose tissue using 
computed tomography (CT) -guided biopsy sampling. At autopsy (t2), samples from the same body regions 
were collected manually. Additionally, urine, heart blood (left ventricle), gastric content, brain samples and hair 
were collected. Butyrfentanyl concentrations and relative concentrations of the metabolites carboxy-, hydroxy-, 
nor-, and desbutyrfentanyl were determined by LC-MS/MS and LC-QTOF. At t1, butyrfentanyl concentrations 
were 66 ng/mL in femoral blood, 39 ng/mL in heart blood, 110 ng/g in muscle, 57 ng/g in liver, 160 ng/g in 
kidney, 3100 ng/g in lung, 590 ng/g in spleen and 550 ng/g in adipose tissue. At t2, butyrfentanyl concentration 
in urine was 1100 ng/mL, in gastric content 2000 ng/mL, in hair 11000 pg/mg and brain concentrations ranged 
between 200-340 ng/g. Carboxy- and hydroxybutyrfentanyl were identified as most abundant metabolites. 
Comparison of t1 and t2 showed a concentration increase of butyrfentanyl in femoral blood of 120%, in heart 
blood of 55% and a decrease in lung of 30% within 19 hours. No clear concentration changes could be observed 
in the other matrices. Postmortem concentration changes were also observed for the metabolites. In conclusion, 
butyrfentanyl seems to be prone to postmortem redistribution processes and concentrations in forensic death 
cases should be interpreted with caution.  
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Butyrfentanyl belongs to the group of fentanyl-derived designer drugs which includes e.g. α-methylfentanyl, 4-
fluorofentanyl, 3-methylfentanyl or acetylfentanyl. Increasing numbers of fentanyl consumption and occurrence 
of new fentanyl analogues have been observed [1-3], however mostly with little knowledge on pharmacological 
potency or pharmacokinetic and physicochemical properties. Also for butyrfentanyl, pharmacokinetic 
parameters are not known. They can only be assumed to be similar to fentanyl, which has a volume of 
distribution (Vd) of 3-8 L/kg and a pKa of 8.4 [4]. Butyrfentanyl potency ratio was found to be 7 compared to 
morphine and 0.13 compared to fentanyl [5]. Metabolism of fentanyl-derived designer drugs was investigated 
for 3-methylfentanyl and isofentanyl and was found to be similar to fentanyl, where the nor-metabolite shows 
highest abundance [6, 7]. Prevalence or tissue distribution of butyrfentanyl metabolites has not been investigated 
to date, although a similar metabolism pathway to fentanyl and/or 3-methylfentanyl seems to be likely. Several 
poisoning cases with fentanyl analogues have been reported to date [2, 3, 8]; however, only few forensic case 
reports with butyrfentanyl involved are published and postmortem concentrations were presented only in one 
case [9-11]. Besides missing information on actual pharmacodynamic and –kinetic properties, interpretation of 
these postmortem concentrations needs to be done with great caution, as also information on postmortem 
redistribution (PMR) of butyrfentanyl does not exist so far. PMR complicates interpretation of forensic death 
cases with drugs involved. Several mechanisms such as e.g. drug degradation, new formation or diffusion 
processes can contribute to PMR and are believed to be time-dependent [12]. Basic drugs are believed to 
redistribute due to their increased ionization in the more acidic environment after death. Lipophilic drugs that 
have an apparent volume of distribution (Vd) > 3 L/kg, a high concentration ratio between central and peripheral 
blood (C/P ratio) or between the liver and peripheral blood (L/P ratio) are said to redistribute more than others 
due to their inhomogeneous distribution within the body at time of death [13-16]. However, prediction of PMR 
cannot be done only based on Vd as the correlation is not very strong [17]. Data on time-dependent PMR is 
generally rare and mainly exists for classical drugs such as opiates, benzodiazepines, antidepressants or 
antipsychotics to date [18-20]. Time-dependent PMR of NPS has not been investigated so far. However, new 
psychoactive substances (NPS) are an emerging problem in forensic toxicology with many intoxication cases 
reported [1]. PMR of NPS can only be assumed based on structural similarities to known substances or 
estimated based on their physicochemical properties such as e.g. lipophilicity or pKa. Giving the structural 
similarities to fentanyl – a drug that is known for significant postmortem concentration increases in peripheral 
blood [21, 22] – PMR of butyrfentanyl seems to be likely. The aim of this work was to investigate tissue 
distribution and time-dependent PMR of butyrfentanyl and its main metabolites. 
Case history  
The dead body of a 23 year old male was found lying in the bathroom of his apartment. In his bedroom, a tray 
with traces of white powder and a tube was found. History of drug use was known. The external postmortem 
examination revealed no injuries or signs of a violent cause of death. The time of death was estimated as 2 to 4 
hours prior to the medical examination. Further examination revealed few fresh appearing bruises on the right 
knee and the tibia, a single fresh abrasion on the base of the left neck and small fresh bleedings in the left 
temporal muscle and the left muscle between shoulder and tongue (omohyoid). Postmortem computed 
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tomography (CT) imaging and the autopsy revealed few unspecific intoxication signs such as edema of the brain 
and a moderate full urinary bladder. Small amounts of residual white powder were found in the nose.  
Material and methods 
Chemicals and reagents 
A methanolic solution (1 mg/mL) of n-butyrfentanyl was obtained from Cayman Chemical (delivered by 
Adipogen AG, Arlesheim, Switzerland) and a methanolic solution of the deuterated internal standard (IS, 0.1 
mg/mL) fentanyl-d5 was obtained from Lipomed (Arlesheim, Switzerland). Water was purified with a Purelab 
Ultra millipore filtration unit (Labtech, Villmergen, Switzerland), acetonitrile of HPLC grade was obtained from 
Fluka (Buchs, Switzerland) and all other chemicals used were obtained from Merck (Zug, Switzerland). 
Postmortem samples 
Blood and alternative matrices were collected at two time points t1 and t2 after death according to [23]. After 
the routine CT imaging procedure (t1, 9 hours after death) on a 128-slice scanner (Somatom Definition Flash, 
Siemens Medical Solutions, Forchheim, Germany), introducer needles were placed into the right heart ventricle, 
the right lung, the right lobe of the liver, the right kidney, the spleen, subcutaneous adipose tissue of the waist, 
muscle tissue at the upper left thigh, the right femoral vein and the dural sac at the level of the lumbosacral 
junction using the virtobot system [23]. After placement of the introducer needles, another CT scan was 
performed to verify the needle positions. From the right heart ventricle and the femoral vein, 1 mL blood was 
collected using a 5 mL syringe. Cerebrospinal fluid was not available. Biopsies of approx. 22 mm length and 20 
mg weight from tissues and organs were collected in triplicates from all matrices. Directly after sample 
collection, the biopsies were weighted into 2 mL Metal Bead Lysing Matrix tubes (MP Biomedicals, Illkirch, 
France). The body fluids were aliquoted in triplicates of 20 µL into 2 mL Eppendorf Safe Lock Tubes 
(Schoenenbuch, Switzerland). The following day at autopsy (t2, 28 hours after death), samples from the same 
locations were collected where biopsies had been taken at t1. Additionally, heart blood from the left ventricle, 
urine, gastric content, a sample from the left lobe of the liver, cerebellum, frontal lobe, centrum semiovale, 
thalamus, praecuneus, a hair sample representing the full hair length (2 cm) from the occipital head region and a 
nose swab were collected. After autopsy, the solid matrices were aliquoted into triplicates of approx. 20 mg and 
body fluids into triplicates of 20 µL. All samples were stored at -20 °C until analysis.  
Routine systematic toxicological analysis 
Routine toxicological analysis was performed on femoral blood and urine collected at t2 (autopsy samples). 
Urine was screened initially by a cloned enzyme donor immunoassay (CEDIA®) for drugs of abuse (opiates, 
cocaine, cannabis, amphetamines, methadone, barbiturates, benzodiazepines, and lysergic acid diethylamide 
(LSD)) followed by a gas chromatography mass spectrometry (GC-MS) screening after enzymatic conjugate 
cleavage using Helix pomatia N., liquid-liquid extraction and semi-automatic data analysis in AMDIS adapted 
from Maurer/Pfleger/Weber [24]. Femoral blood was additionally screened for drugs by an untargeted LC-
MS/MS ion trap screening after simple protein precipitation (Bruker amazon®, Maurer/Wissenbach/Weber 
database [25]) and for ethanol and other volatile compounds by headspace GC flame ionization detector (HD-
GC-FID). Quantification of drugs in femoral blood was performed by LC-MS/MS [26].  
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Sample preparation for PMR investigation 
Extraction of tissue and body fluid samples were performed according to Staeheli et al. [27]. Briefly, organ and 
tissue samples were homogenized using a Fast Prep®-24 Instrument (MP Biomedicals, Illkirch, France). To 
each sample, fentanyl-d5 (40 ng/mL) was added. Two liquid-liquid extractions (LLE) with butyl acetate/ethyl 
acetate (1:1, v/v) were performed, one at pH 7.4 and one at pH 13.5. The extracts were combined, evaporated to 
dryness and reconstituted in 60 µL mobile phase.  
LC-MS/MS analysis of butyrfentanyl 
The quantitative butyrfentanyl analysis of all samples was performed using a Thermo Fischer Ultimate 3000 
UHPLC system (Thermo Fisher, San Jose, California, USA) coupled to a Sciex 5500 QTrap linear ion trap 
quadrupole MS (Sciex, Darmstadt/Germany). The MS was operated in the unscheduled multiple reaction 
monitoring (MRM) mode using eight transitions for butyrfentanyl. Four transitions corresponded to the 12C 
isotope and four transitions corresponded to the 13C isotope of butyrfentanyl. Quantifier transitions for 
butyrfentanyl and its 13C isotope were 351→188 resp. 352→189, and 342→188 for fentanyl-d5. Remaining MS 
settings were according to [27]. An LC gradient elution was performed using a Phenomenex (Aschaffenburg, 
Germany) Synergy Polar RP column (100 x 2.0 mm, 2.5 µm) with 10 mM ammonium formate buffer in water 
containing 0.1% (v/v) formic acid (pH 3.5, eluent A) and acetonitrile containing 0.1% (v/v) formic acid (eluent 
B) according to [27]. The MS was controlled by Analyst® 1.6.2 software and quantitation was performed with 
MultiQuant® 2.1.1 software. Butyrfentanyl concentrations in urine, lung, adipose tissue, gastric content and hair 
were calculated using the 13C calibration, which avoided detector saturation problems. Concentrations of all 
other samples were calculated with the 12C calibration. For the analysis of the hair sample, the calibration range 
was extended to 12000 pg/mg (not validated). Percentage concentration increase or decrease between t1 and t2 
for each matrix was calculated. The concentration ratios between the matrices and peripheral blood were 
calculated for t1 and t2. 
LC-HRMS analysis of butyrfentanyl metabolites 
Investigation of the metabolites was performed on a Thermo Fischer Ultimate 3000 UHPLC system coupled to a 
Sciex 6600 QTOF System. The instrument was operated in the TOF MS mode with information dependent 
acquisition (IDA) of product ions. IDA criteria were set according to [28]. The LC start conditions were 10% 
eluent B for 1 min with a flow rate of 0.5 mL/min, 2-18 min to 95% B, hold for 1 min and 0.5 min 
reequilibrating to 10% B. Injection volume was 10 µL. The MS was controlled by Analyst® TF 1.7 software 
and data analysis was performed with PeakView® 2.1 and MultiQuant® 2.1.1 software. LC-QTOF data was 
screened for the exact masses of butyrfentanyl, norbutyrfentanyl, carboxybutyrfentanyl, hydroxybutyrfentanyl 
and desbutyrfentanyl (Table 1). The metabolite relative concentrations were calculated by dividing the 
metabolite peak areas by the area of fentanyl-d5 (area ratio). Then the relative concentration changes between t1 
and t2 were investigated. Additionally, the metabolite ratios were analyzed by dividing the relative 




Hair analysis: sample preparation and LC-MS/MS analysis 
Extraction of the non-segmented hair sample was performed according to [29]. Before extraction, fentanyl-d5 
(2500 pg/mg) was added as IS for the butyrfentanyl quantitation. Furthermore, the first wash solution (water) 
was also investigated after spiking the solution with the same IS and acidification. Then both samples, the 
extract of the lock of hair and the wash solution, were dried and reconstituted in 500 µL mobile phase. Analysis 
on butyrfentanyl was performed by LC-MS/MS as described above. Hair analysis on other drugs was performed 
using validated routine LC-MS/MS methods which are not described in this case report. 
LC-MS/MS method validation 
The butyrfentanyl quantitation method was validated in terms of selectivity, matrix effects, accuracy, precision, 
calibration model and limit of quantitation in postmortem femoral blood according to [30]. 
Selectivity 
Six blank postmortem blood samples from different sources and two blank postmortem blood samples spiked 
with IS (zero samples) were analyzed for interfering peaks with butyrfentanyl and fentanyl-d5.  
Calibration 
Ten calibrators were prepared in duplicates at concentrations 1, 5, 25, 100, 200, 500, 1000, 1500, 2000 and 2500 
ng/mL. For calibrators 1-6 (1-500 ng/mL), the 12C isotope of butyrfentanyl was used as quantifier. For 
calibrators 5-10 (200-2500 ng/mL) the 13C isotope was used as quantifier. The regression lines for both 
calibrations 12C and 13C were calculated using a simple linear model with 1/X weighting to compensate for 
heteroscedasticity. Back calculation of the calibrator concentrations should result in less than ± 20% bias to the 
theoretical concentration.  
Accuracy and precision 
Six replicates of quality control (QC) samples at the concentrations levels QC low (2 ng/mL), QC med (300 
ng/mL) and QC high (2250 ng/mL) were analyzed each on the same day. Concentration of QC low was 
calculated using 12C calibration (1-500 ng/mL) and the concentration of QC high was calculated using 13C 
calibration (200-2500 ng/mL). QC med concentration was determined with both calibrations. Accuracy was 
calculated as the percent deviation of the mean calculated concentration at each concentration level from the 
corresponding theoretical concentration. Precision was calculated as the relative standard deviation (RSD) 
within the QC levels. 
Matrix effect 
Matrix effect was investigated with six blank postmortem blood samples from different sources at the 
concentrations levels of QC low and QC high according to [30].  
Limits 
The limit of quantitation (LOQ) was defined as the concentration of the lowest calibrator (1 ng/mL) fulfilling 
the criteria of signal to noise 10:1 and back-calculated concentrations within +/- 30% of theoretical 





Routine systematic toxicological analysis 
CEDIA® immunoassays in urine were positive for benzodiazepines and LSD. The LC-Ion Trap MS and the 
GC-MS screening revealed benzoylecgonine, hydroxymidazolam and a clarithromycin metabolite. Quantitative 
analysis in femoral blood gave negative results for cocaine, LSD and fentanyl. Benzoylecgonine and midazolam 
were below the limit of quantification of 1.25 and 11 ng/mL, respectively and 1.0 ng/mL hydroxymidazolam 
was quantified. Ethanol or other volatiles were not detectable. 
LC-MS/MS method validation 
No interfering peaks were detected in the blank postmortem blood and zero samples. For both 12C and 13C 
calibration a linear regression model with 1/X weighting was used. R2 value was 0.99 for both calibrations. No 
difference between 12C and 13C calibration was observable for QC med. Validation results including accuracy, 
precision and matrix effects are given in Table 2.  
Butyrfentanyl analysis 
Butyrfentanyl concentrations were successfully determined in all samples and are displayed in Figure 1. At t1, 
highest concentrations of 3000 ng/g were found in lung tissue. Spleen and adipose tissue showed similar 
concentrations of 590 and 550 ng/g, respectively. Lower concentrations were found in kidney (160 ng/g), 
muscle (110 ng/g), liver (57 ng/g), femoral blood (66 ng/mL) and heart blood (39 ng/mL). Concentration ratios 
between the matrices and femoral blood are given in Table 3. At t2, concentration in the left lobe of the liver 
was 30% higher compared to the right lobe, although concentration ranges were overlapping. In gastric content 
2000 ng/mL butyrfentanyl were measured. In brain tissue, mean concentrations of 200 ng/g were measured 
except for centrum semiovale, where the mean concentration was 340 ng/g. A concentration change during the 
19 hours between the two sampling time points was observed in peripheral blood (+120%), heart blood (+55%) 
and lung tissue (-30%). Muscle, liver, kidney and adipose tissue showed mean concentration changes with 
overlapping concentration ranges between t1 and t2. Qualitative analysis (routine screening method) of the nose 
swab revealed butyrfentanyl. 
Butyrfentanyl metabolites 
The investigated butyrfentanyl metabolites were detected in all matrices at both time points except for 
norbutyrfentanyl, which in general showed low abundance and was not detected in adipose tissue at t1. At t2, 
norbutyrfentanyl was only detectable in urine, kidney and liver tissue. Next to the highest abundant peak, the 
extracted ion chromatogram of hydroxybutyrfentanyl indicated the presence of several potential minor isomers 
that were not further investigated. Present fragment ions of the highest abundant hydroxybutyrfentanyl peak in 
the MS/MS were 188.1436, 105.0694 and 281.2023. 
The metabolite ratios (metabolite area/mean butyrfentanyl area) displayed in Figure 2 showed general highest 
metabolite abundance in urine, kidney and liver. In blood, carboxybutyrfentanyl was the most abundant 
metabolite at t1 followed by hydroxybutyrfentanyl. In tissues, hydroxybutyrfentanyl showed highest abundance 
followed by carboxybutyrfentanyl. Des- and norbutyrfentanyl were found in relatively low amounts in all 
matrices except for liver and kidney, where the metabolite ratios were higher. The metabolite ratios in different 
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brain regions were rather homogeneous with carboxybutyrfentanyl as the lowest abundant metabolite after 
norbutyrfentanyl which was not detected. In Figure 2, metabolite ratios in the cerebellum are exemplarily 
displayed for all brain regions.  
Comparison of the relative metabolite concentrations between t1 and t2 showed a decrease of carboxy- and 
norbutyrfentanyl in all matrices. Desbutyrfentanyl concentrations increased between t1 and t2 in blood and 
stayed on a similar level in other matrices. In contrast, hydroxybutyrfentanyl area ratios stayed on the same level 
in blood, but decreased in tissues. In Figure 3, the results are exemplarily displayed for blood, muscle, liver and 
kidney. 
Hair analysis 
In the hair sample 11000 pg/mg butyrfentanyl were detected and in the wash solution 3500 pg/mg. Highest 
abundant metabolite was hydroxybutyrfentanyl with a metabolite ratio of 0.01 in the hair sample and 0.006 in 
the wash solution, respectively. Other metabolites showed a metabolite ratio in the hair extract below 0.002. 
Further drugs detected were cocaine (7600 pg/mg), benzoylecgonine (1200 pg/mg), norcocaine (160 pg/mg), 
amphetamine (240 pg/mg), midazolam (20 pg/mg), α-hydroxymidazolam (< LOQ), and ketamine (300 pg/mg). 
Discussion 
So far butyrfentanyl blood concentrations are reported only for few cases. In three non-lethal cases with mixed 
intoxications (combination with either fentanyl or acetylfentanyl) butyrfentanyl ranged from not detected to 0.9 
ng/mL in serum and from 2 to 66 ng/mL in urine [10]. In a fatal case, 58 ng/mL butyrfentanyl was measured in 
peripheral blood in combination with acetylfentanyl [9]. In our case, standard toxicological analysis did not 
reveal drugs in relevant concentrations. Standard toxicological analysis was unable to detect butyrfentanyl due 
to a missing library entry both in GC and LC-MS analysis. Only manual evaluation of the GC-MS urinary data 
revealed a mass of 145 representing a characteristic fragment ion of fentanyl, and careful mass spectra 
interpretation lead to an initial hint for butyrfentanyl. These findings could be further confirmed by manual 
evaluation of LC-Ion Trap data files and finally proven by comparison to a commercially available reference 
standard. The positive immunoassay result on LSD can probably be explained by cross reactivity with 
butyrfentanyl, as cross reactivity with fentanyl is already well known [31]. Missing competing causes of death 
(both toxicological and medicinal) lead to the conclusion, that an intoxication with butyrfentanyl was most 
probably the cause of death; thus, representing the first report on fatal butyrfentanyl monointoxication. The 
white powder residues in the nose turned out to be butyrfentanyl, which suggests sniffing of the drug as route of 
application. Hair analysis revealed a former drug history of cocaine, amphetamine, and ketamine over the past 
two months prior to death and proved the intake of low amounts of midazolam. Furthermore, the entire lock of 
hair was positive for butyrfentanyl at a level 11000 pg/mg. However, a wash ratio (concentration of wash 
solution/concentration in hair) of 0.32 together with very low metabolic ratios for the different metabolites 
detected in hair and in the wash solution are indicators of a current sweat-mediated external contamination. This 
phenomenon is often observed in cases of acute opioid intoxication leading to death e.g. due to sweating during 
an agonal phase.  
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A short one day method validation was performed for butyrfentanyl in postmortem blood as proposed by Peters 
and Drummer [30] for analysis of rarely occurring compounds. Validation exclusively in blood is of course 
generally not sufficient to evaluate the method performance on other matrices such as postmortem tissues. 
However, in the current study butyrfentanyl was included in an already existing method for 83 drugs in 11 
different postmortem matrices. The former validation showed that accuracy and precision of the applied method 
was within the required ranges for the majority of the analytes in most matrices as long as an IS was used [27]. 
Only QC low precision exceeded the required limit minimally, which was considered as acceptable due to 
analysis of triplicate samples in the case investigation. In the presented study, calibration was done in 
postmortem blood instead of solvent, which should lead to a further improvement of accuracy. Comparison 
between time points was performed in a relative manner anyway. Therefore, validation only in postmortem 
blood was chosen as a compromise between extensive method validation and significance of the expected 
findings and the resulting accuracy and precision were considered as acceptable. 
Distribution of butyrfentanyl within the body was inhomogeneous. The rather high concentration ratio between 
lung and femoral blood of 46 could be explained by the nasal application which may have led to inhalation of a 
part of the powder. Furthermore, the high perfusion rate of the lung in combination with lysosomal trapping may 
have been involved in the accumulation of butyrfentanyl in the lung as it is a rather lipophilic substance 
(calculated logP of 4.44 by ALGOPS 2.1) with a pKa probably around 8 [32]. Gastric content showed high 
concentrations as well, which might have resulted from swallowing of powder after nasal application or 
secretion into the acidic gastric content after absorption. In brain, mean concentrations were approx. 1.5 times 
higher compared to femoral blood, except for the centrum semiovale, where the mean concentration was higher. 
As the centrum semiovale (white matter) has a higher lipid content compared to the other brain regions, 
butyrfentanyl may have showed an increased affinity to this brain region [33].  
No time-dependent PMR data for fentanyl-derived designer drugs was available so far. However, studies on 
PMR of fentanyl revealed increases in postmortem concentrations in peripheral blood and no correlation 
between antemortem and postmortem blood concentrations [21, 34]. Butyrfentanyl concentration in femoral 
blood aligned with the concentrations in muscle tissue during the two sampling time points. Therefore, PMR in 
femoral blood may have been caused by butyrfentanyl diffusion from surrounding muscle tissue into femoral 
blood. The concentration increase in heart blood might have been caused by redistribution processes from the 
lung, where highest concentrations were detected. This redistribution mechanism may also explain the higher 
butyrfentanyl concentrations in the left heart ventricle compared to the right ventricle due to e.g. blood 
movement along the pulmonary veins. Also other adjacent tissues like heart muscle or stomach might have been 
involved; however, concentration in heart muscle was not determined. Butyrfentanyl heart to femoral blood 
concentration ratio of 0.6 at t1 in our case showed, that a C/P ratio < 1 might not always be a trustworthy 
criterion to exclude PMR processes within a case. Furthermore, liver to peripheral (L/P) ratio was < 1 at both 
time points and does not support the thesis of drugs with L/P ratios < 5 being less prone to PMR [35], at least 
within a case. An explanation for the unexpected low concentrations in liver compared to blood might have 
resulted from a relatively fast death after intake of the substance and the resulting short time window for drug 
distribution and accumulation. However, the relatively high concentration in e.g. adipose tissue which has a 
rather low perfusion rate contradicts this theory. Whether these relatively high concentrations in adipose tissue 
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resulted from the latest consumption or from an additional earlier intake cannot be differentiated. A general 
limitation of the study was lack of information on the postmortem interval between death and first sampling 
time point, which could not be analyzed due to practical reasons. Therefore no conclusions could be made on 
PMR in the first hours after death, which are believed to be a time interval in which relevant redistribution 
processes occur [36]. 
No information on butyrfentanyl metabolism and metabolite tissue distribution was available so far. Therefore, 
few phase I metabolites expected to occur in analogy to fentanyl [7] or 3-methylfentanyl [6] were included in 
the analysis of time-dependent PMR. Phase II metabolites were not investigated, as their extraction from the 
biological matrices could not be expected with the applied sample preparation. Due to lack of reference 
material, absolute quantification of the chosen metabolites was not possible and consequently, analytical 
recovery, accuracy and precision could not be determined. Estimations on abundance are based on area ratios 
relative to the parent drug, of course also not considering different ionization properties and MS response. 
Precision of extraction was partly covered by analysis of triplicates and revealed comparable results like 
butyrfentanyl itself and should therefore allow relative comparison between time points. The extracted ion 
chromatogram of m/z 367.2380 indicated the presence of several other potential isomers next to the evaluated 
highest hydroxybutyrfentanyl metabolites. Fragment ions of the highest peak indicated hydroxylation of the 
alkyl side chain. However, the main focus of the presented work was not the elucidation of butyrfentanyl 
metabolism, but rather its postmortem behavior. Further structure elucidation was therefore omitted.  
In contrast to fentanyl – where norfentanyl is the most abundant metabolite in blood [4, 7] –
hydroxybutyrfentanyl and carboxybutyrfentanyl showed highest abundance in this butyrfentanyl case. A 
possible reason for the higher abundance of the carboxy-metabolite in the butyrfentanyl metabolism might be 
the longer alkyl chain in comparison to fentanyl or 3-methylfentanyl, which might enhance interaction with 
alcohol and aldehyde dehydrogenases. 
As expected, the metabolite ratios in adipose tissue were relatively low, which can be explained by their higher 
hydrophilicity compared to the parent compound. The rather high metabolite abundance in liver, kidney and 
urine correlates with the higher abundance of metabolizing enzymes in these organs and their excretion 
pathway. Interestingly, the metabolite ratio of carboxybutyrfentanyl in brain was lower compared to all other 
matrices and compared to hydroxy- and desbutyrfentanyl. This low abundance in brain could be explained by 
the higher hydrophilicity of carboxybutyrfentanyl compared to the other metabolites, which might have 
prevented its crossing of the blood brain barrier (BBB). Additionally, it does not seem to be transported 
extensively. However, it is not clear whether hydroxy- and desbutyrfentanyl entered the brain by crossing the 
BBB or if direct formation in the brain could have occurred. Comparison of the relative metabolite 
concentrations at t1 and t2 also showed apparent concentration changes. Especially norbutyrfentanyl was prone 
to great concentration losses between the time points and was not detectable anymore in several matrices at t2. It 
therefore stays unclear, whether norbutyrfentanyl is a minor metabolite compared to hydroxy- or 
carboxybutyrfentanyl or if its low concentrations resulted from postmortem degradation or redistribution 




A fatal case of butyrfentanyl poisoning revealed relevant postmortem concentration increases of butyrfentanyl in 
femoral and heart blood within 19 hours after first sampling. Highest abundant metabolites were 
hydroxybutyrfentanyl and carboxybutyrfentanyl. While hydroxybutyrfentanyl concentration stayed constant in 
peripheral blood, carboxybutyrfentanyl concentration decreased. Consequently, postmortem butyrfentanyl 





Artwork and Tables 
Table 1 Chemical formulas, exact masses and structures of butyrfentanyl and its metabolites 
Analyte Chemical formula Exact mass [M+H]+ Structure 
Butyrfentanyl C23H30N2O 351.2431 
 
Carboxybutyrfentanyl C23H28N2O3 381.2173 
 
Hydroxybutyrfentanyl C23H30N2O2 367.2380 
 
Desbutyrfentanyl C19H24N2 281.2012 
 
Norbutyrfentanyl C15H22N2O 247.1805 
 
 









Matrix effect  
± RSD [%] 
Matrix effect  
± RSD [%] 
IS corrected 
Low 2.0 12C 21 97 75 ± 15 93 ± 3.8 
Med 300 12C 4.1 108 - - 
Med 300 13C 4.3 115 - - 
High 2250 13C 4.6 94 106 ± 10 104 ± 2.9 
 
Table 3 Butyrfentanyl concentration ratios between the matrices and femoral blood. Unavailable samples are 
indicated by “-“. 
Matrix t1 t2 
Heart blood right ventricle 0.6 0.4 
Heart blood left ventricle - 0.5 
Urine - 7.6 
Muscle 1.6 1 
Liver l. dexter 0.9 0.5 
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Liver l. sinister - 0.6 
Kidney 2.4 1.3 
Lung 46 14 
Spleen 8.8 3.3 
Adipose tissue 8.3 5.5 
Gastric content - 14 
Frontal lobe - 1.5 
Thalamus - 1.4 
Cerebellum - 1.6 
Centrum semiovale - 2.3 
Praecuneus - 1.6 










Figure 2 Mean metabolite ratios (relative metabolite concentration divided by mean butyrfentanyl relative 
concentration) and range (n=3) in femoral blood, heart blood, muscle, liver, kidney and lung tissue at t1 and in 





Figure 3 Relative concentration changes of the metabolites between t1 and t2 displayed as mean relative 
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